9 Results for "

prolonged action

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "prolonged action" in MCE Product Catalog:

29
29 Cited Publications
Cat. No.: HY-17504A
CAS No.: 287714-41-4
Synonyms: ZD 4522
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
loading...
    loading...
Cat. No.: HY-17504AS1
CAS No.: 2070009-40-2
Synonyms: ZD 4522-d6
Rosuvastatin-d6 (ZD 4522-d6) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
loading...
    loading...
Cat. No.: HY-17504AS
CAS No.: 1133429-16-9
Synonyms: ZD 4522 d3
Rosuvastatin-d3 is the deuterated-labeled Rosuvastatin (HY-17504A). Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
loading...
    loading...
Cat. No.: HY-101199
CAS No.: 1206487-81-1
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

N-Benzylnaltrindole hydrochloride is a potent δ2-selective opioid receptor antagonist. Benzylnaltrindole hydrochloride has a long duration of action in vivo than Naltriben (NTB). N-Benzylnaltrindole hydrochloride iserve as a useful tool in the pharmacologic characterization of δ-opioid receptor function .
loading...
    loading...
Cat. No.: HY-14297
CAS No.: 652990-07-3
Target:  

Adrenergic Receptor

Research Areas:  

Endocrinology

Milveterol is a long-acting β(2)-adrenoceptor agonist with high binding activity. Milveterol exhibits high potency in vitro and a prolonged duration of action in a guinea pig bronchoprotection model. Milveterol has been structurally optimized to show enhanced binding potency compared to its parent monomer .
loading...
    loading...
Cat. No.: HY-179356
CAS No.: 1413439-62-9
Target:  

PTHR

Research Areas:  

Endocrinology

Octadecyl β-D-glucopyranosiduronic acid (Compound 9) is a parathyroid hormone 1 receptor (PTH1R) activator, with a pEC50 value > 9. Octadecyl β-D-glucopyranosiduronic acid can be used for research on hypoparathyroidism .
loading...
    loading...
Cat. No.: HY-178141
AChE/BuChE-IN-7 is a dual-action inhibitor with an IC50 valueof 0.15 μM for AChE and 0.7 μM for BuChE, SI of 4.7. AChE/BuChE-IN-7 shows anti-oxidant activity and can mitigate H2O2-induced cytotoxicity. AChE/BuChE-IN-7 has genomic stability and prolonged systemic availability. AChE/BuChE-IN-7 can be used for the research of neurological disease, such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-17504AR
CAS No.: 287714-41-4
Synonyms: ZD 4522 (Standard)
Rosuvastatin (Standard) is the analytical standard of Rosuvastatin (HY-17504A). This product is intended for research and analytical applications. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
loading...
    loading...
Cat. No.: HY-L040
1,172 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.